Amgen

Description

Patients. For 45 years. From genetics to genomics, and now more than ever to artificial intelligence, Amgen has always made therapeutic innovation a priority to improve the lives of millions of people around the world. Over the decades, the company has become a global leader in biotechnology, pushing the boundaries of science to accelerate the research and development of new treatments for the most serious diseases. Present in France since 1990, Amgen today has more than 360 employees, 20% of whom are dedicated to R&D. With around 20 medicines and numerous public/private partnerships, Amgen France has become a key player in the health innovation ecosystem, holding the strategic position of Amgen’s third-largest subsidiary worldwide in clinical research. Its ambition: to continuously advance the care of patients suffering from cancer, cardiovascular, inflammatory, or kidney diseases, as well as rare diseases. What will the health of tomorrow look like? Follow our news on www.amgen.fr and on social media @AmgenFrance. #WeAreBiotech